Constipation as a possible predictor of poor treatment response in chronic migraine: A retrospective study of anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies and the impact of switching
Background There is a growing awareness of constipation being a side effect of anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies (mAbs). This study aims to assess constipation as a side effect and explore its potential role as a predictor of treatment response in chronic migrain...
Saved in:
Main Authors: | Sena Uzun (Author), Ulf Frejvall (Author), Per Petersson (Author), Gürdal Sahin (Author) |
---|---|
Format: | Book |
Published: |
SAGE Publishing,
2024-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New Trends in Migraine Pharmacology: Targeting Calcitonin Gene-Related Peptide (CGRP) With Monoclonal Antibodies
by: Damiana Scuteri, et al.
Published: (2019) -
Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs-Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies
by: Danuta Szkutnik-Fiedler
Published: (2020) -
Anti-CGRP monoclonal antibodies in the treatment of migraine in women: impact on menstrual relared migraine and algodysmenorrhea
by: Anna V. Berdnikova, et al.
Published: (2023) -
Calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraines in adults
by: Eric R Ocheretyaner, et al.
Published: (2022) -
Calcitonin Gene-Related Peptide (CGRP)-Targeted Treatments-New Therapeutic Technologies for Migraine
by: Linda Sangalli, et al.
Published: (2023)